Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to sign a consent form agreeing to take part in the study
• Adults aged 18 or older — both men and women are eligible
• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), either through clinical assessment or laboratory/tissue testing, and who have not previously received any systemic (whole-body) treatment for this cancer — such as targeted drug therapy, chemotherapy, or immunotherapy
• People who have a specific type of blood clot blocking the portal vein (the main blood vessel supplying the liver), classified as Type VP3 or VP4 (confirm with trial site)
• People who have at least one measurable area of cancer that can be detected on imaging scans, following standard measurement guidelines (RECIST v1.1), that has not been treated with radiation — or, if it has been treated locally, where the cancer has been confirmed to have grown back
• People whose liver function scores within an acceptable range (Child-Pugh score of 7 or below, meaning Class A or B liver function) (confirm with trial site)
• People whose largest liver tumour measures 7 centimetres or more across
• People who are relatively well and able to carry out daily activities, rated 0 or 1 on a standard activity scale (ECOG scale) (confirm with trial site)
• People whose doctors estimate they are likely to survive for at least 12 weeks
• People whose blood and organ function test results fall within the ranges required by the study, including acceptable levels of white blood cells, platelets, red blood cells, liver enzymes, kidney function, and protein levels (confirm with trial site for specific values)
• People of reproductive potential who agree to use reliable contraception during the trial and for at least 180 days after the last dose; women who could become pregnant must have a negative pregnancy blood test within 7 days before starting the study drug

Who may not be able to join:

• People whose liver cancer is a less common subtype, such as fibrolamellar, sarcomatoid, mixed, or bile duct-related types, confirmed by tissue or cell testing
• People who have an active autoimmune disease (where the immune system attacks the body), or a history of one that could return — such as autoimmune hepatitis, certain lung, eye, gut, or kidney conditions, or thyroid disorders (some exceptions may apply — confirm with trial site)
• People who have taken immune-suppressing medicines or high-dose steroid tablets (above a certain dose) within 2 weeks before starting the study drug
• People who currently have, or have a history of, certain lung inflammation conditions (such as interstitial lung disease or pulmonary fibrosis) that could complicate treatment, or who show signs of active pneumonia on a chest scan, or have severely reduced lung function
• People with confirmed active tuberculosis of the lungs
• People who are known to be allergic to the study drugs or to similar types of medicines (monoclonal antibodies or anti-cancer targeted drugs)
• People with a known history of cancer that has spread to the brain or spinal cord, or who have had hepatic encephalopathy (a brain condition caused by liver failure)
• People who have previously had a stem cell transplant or an organ transplant from another person
• People with moderate to severe fluid build-up in the abdomen requiring drainage, or with significant uncontrolled fluid around the lungs or heart
• People with serious heart or blood vessel conditions, including dangerous heart rhythm problems, recent heart attack, stroke, heart failure, or poorly controlled high blood pressure (confirm with trial site for specific thresholds)
• People with blood clotting problems, a recent history of significant bleeding, blood clots or blockages in blood vessels within the past 6 months, or who are on certain blood-thinning or anti-clotting medications
• People with a history of bleeding from varicose veins in the oesophagus or stomach caused by liver-related pressure problems within the past 6 months, or who have been found to have high-risk varicose veins on recent scope examination
• People who have had a life-threatening bleeding event within 3 months before starting the study drug
• People with a history of a hole or abscess forming in the abdomen within the past 6 months
• People with a history of bowel blockage, or current signs of one, within the past 6 months
• People with serious wounds that have not healed, active ulcers, or untreated broken bones
• People with significant levels of protein in their urine confirmed by a 24-hour urine test
• People who have had a serious infection within the past 4 weeks, or who are currently being treated with antibiotics for an active infection, or who have had an unexplained high fever within the past 7 days
• People with a weakened immune system from birth or due to a condition such as HIV, or people with confirmed active syphilis
• People who have had another type of cancer within the past 5 years (some exceptions apply for certain minor skin cancers and other early-stage cancers that have been fully treated — confirm with trial site)
• People who have had liver surgery, local liver cancer treatment, or taken an experimental drug within 4 weeks before starting the study, or certain traditional herbal medicines with anti-cancer effects within 2 weeks before starting
• People who have taken immune-modifying medicines (such as interferon or interleukin) within 2 weeks before starting the study drug
• People who are currently taking part in another clinical trial or have taken an experimental drug within 4 weeks before starting
• People who have received a live vaccine within 4 weeks before starting, or who are expected to need one during or shortly after the study
• People who have had major surgery under general anaesthetic within 4 weeks before starting, or who are expected to need major surgery during the study; or who have had a minor surgical procedure (other than placing a drip line) within 7 days before starting
• Women who are pregnant or breastfeeding, or women who could become pregnant but are unwilling to use contraception
• People with other conditions that the trial doctors believe could affect results or put the person at risk, such as serious alcohol or drug issues, severe mental illness, or major social or family circumstances affecting safety

Important: Always verify eligibility with the trial site directly before applying.